Literature DB >> 25239875

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.

JianYong Zou1, Amos Ela Bella2, ZhenGuang Chen3, XiangQian Han4, ChunHua Su1, YiYan Lei1, HongHe Luo5.   

Abstract

OBJECTIVE: A retrospective single-centre study to compare the clinical features of patients with lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations.
METHODS: Pretreatment medical records of patients with lung adenocarcinoma were reviewed. DNA was extracted from paraffin wax-embedded tumour tissue for analysis of EGFR mutations. Malignant pleural effusion (MPE) was diagnosed by cytopathological testing of pleural fluid.
RESULTS: EGFR mutations (19-Del and L858R) were recorded in 81/283 patients (28.6%). MPE was found in 42/283 patients (14.8%). In patients with stage IV disease, the frequency of EGFR mutations was higher in those with MPE than in those without MPE. EGFR mutations were independently associated with female sex, no history of smoking and presence of MPE.
CONCLUSIONS: There was a positive association between EGFR mutation and the presence of MPE. EGFR mutations may play an important role in the formation of MPE.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  EGFR mutation; Lung adenocarcinoma; malignant pleural effusion

Mesh:

Substances:

Year:  2014        PMID: 25239875     DOI: 10.1177/0300060514539273

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  13 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 2.  Pleural involvement in lung cancer.

Authors:  Theodora Agalioti; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

3.  Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

Authors:  Hanbo Le; Xiaoling Wang; Yao Zha; Jie Wang; Wangyu Zhu; Zhinan Ye; Xiaoguang Liu; Haijie Ma; Yongkui Zhang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

4.  Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.

Authors:  Takashi Inoue; Yuji Matsumura; Osamu Araki; Yoko Karube; Sumiko Maeda; Satoru Kobayashi; Masayuki Chida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-31       Impact factor: 1.520

5.  ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma.

Authors:  Zheng Wang; Xiaonan Wu; Xiaohong Han; Gang Cheng; Xinlin Mu; Yuhui Zhang; Di Cui; Chang Liu; Dongge Liu; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2016-12       Impact factor: 5.087

6.  Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy.

Authors:  Chao-Hua Chiu; Yu-Chung Wu; Chi-Lu Chiang; Lei-Chi Wang; Hsiang-Ling Ho; Chun-Ming Tsai; Yi-Chen Yeh; Wen-Hu Hsu; Teh-Ying Chou
Journal:  Oncotarget       Date:  2017-12-26

7.  EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients.

Authors:  Jinghan Shi; Yang Yang; Yanfeng Zhao; Junjie Zhu; Xiao Song; Gening Jiang
Journal:  Cancer Manag Res       Date:  2019-03-01       Impact factor: 3.989

8.  Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.

Authors:  Audra J Schwalk; David E Ost; Sahara N Saltijeral; Henriette De La Garza; Roberto F Casal; Carlos A Jimenez; Georgie A Eapen; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jack Lee; Yasir Elamin; Jianjun Zhang; Jack A Roth; Stephen Swisher; John V Heymach; Horiana B Grosu
Journal:  Chest       Date:  2020-11-17       Impact factor: 9.410

9.  EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.

Authors:  Meng-Feng Tsai; Tzu-Hua Chang; Shang-Gin Wu; Hsiao-Yin Yang; Yi-Chiung Hsu; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

Review 10.  [Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI].

Authors:  Juan Jiang; Chengping Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.